A drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients).
ChEBI ID: 36063
| Member | Definition | Class |
|---|---|---|
| carbetocin | Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus. | carbetocin |
| carboprost | Prostaglandin F2alpha in which the hydrogen at position 15 is substituted by methyl (S configuration). It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy. | carboprost |
| deaminooxytocin | A heterodetic cyclic peptide that is the synthetic analog of the peptide hormone oxytocin where the free amino group in the half-cystine residue is replaced by hydrogen. The mechanism of action and pharmacological properties of demoxytocin and oxytocin are similar. The drug affects the permeability of the cell membrane, increasing the content of calcium ions in smooth muscle cells, thereby increasing its contraction. It stimulates the contraction of smooth muscles of the uterus, as well as stimulating the contraction of myoepithelial cells of the mammary gland, and enhances the secretion of milk. | demoxytocin |
| dinoprostone | Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. | prostaglandin E2 |
| ergonovine | A monocarboxylic acid amide that is lysergamide in which one of the hydrogens attached to the amide nitrogen is substituted by a 1-hydroxypropan-2-yl group (S-configuration). An ergot alkaloid that has a particularly powerful action on the uterus, its maleate (and formerly tartrate) salt is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced. | ergometrine |
| ergonovine maleate | A maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced. | ergometrine maleate |
| ergotamine | A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. | ergotamine |
| oxytocin | A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour. | oxytocin |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 16,979 (32.73) | 18.7374 |
| 1990's | 11,390 (21.96) | 18.2507 |
| 2000's | 10,188 (19.64) | 29.6817 |
| 2010's | 10,265 (19.79) | 24.3611 |
| 2020's | 3,053 (5.89) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 3,491 (6.32%) | 5.53% |
| Reviews | 3,695 (6.69%) | 6.00% |
| Case Studies | 1,164 (2.11%) | 4.05% |
| Observational | 116 (0.21%) | 0.25% |
| Other | 46,756 (84.67%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 15.0890 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 10.1415 | 9 | 11 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 21.1317 | 1 | 1 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.7019 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 2.2028 | 4 | 5 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0221 | 3 | 3 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 33.4889 | 1 | 1 |
| geminin | Homo sapiens (human) | Potency | 33.4983 | 1 | 1 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 3.5339 | 3 | 3 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 5.0104 | 2 | 3 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8614 | 2 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 26.6011 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 32.1968 | 1 | 1 |
| prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | Potency | 0.1482 | 1 | 1 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 29.9349 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 18.9959 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 23.9145 | 2 | 2 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 23.9145 | 2 | 2 |
| TDP1 protein | Homo sapiens (human) | Potency | 26.1164 | 2 | 3 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 6.1932 | 2 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.0212 | 5 | 5 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 44.6684 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 0.0044 | 1 | 2 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.0025 | 1 | 2 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 0.0044 | 1 | 2 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 0.0027 | 2 | 3 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.0025 | 1 | 2 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 0.0032 | 4 | 5 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.0043 | 1 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0012 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.0038 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.0024 | 1 | 2 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.0385 | 1 | 2 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0200 | 1 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.0385 | 1 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.0200 | 1 | 2 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 0.0215 | 4 | 5 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.0026 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.0012 | 1 | 2 |
| Adenylate cyclase | Arthrospira platensis | IC50 | 70.0000 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.0490 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.0240 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.8411 | 1 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.3154 | 1 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.1464 | 1 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.0669 | 1 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.0120 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0018 | 1 | 1 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 82.1625 | 2 | 4 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | Ki | 331.0750 | 2 | 4 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 4.1420 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 2.3920 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 2.7610 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 1.8980 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 3.8145 | 1 | 2 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 1.9070 | 1 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 0.2782 | 1 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.0927 | 1 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.2857 | 1 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.0972 | 1 | 2 |
| Oxytocin receptor | Homo sapiens (human) | IC50 | 0.0027 | 1 | 1 |
| Oxytocin receptor | Homo sapiens (human) | Ki | 0.0024 | 11 | 13 |
| Oxytocin receptor | Rattus norvegicus (Norway rat) | Ki | 0.0013 | 2 | 2 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 0.0610 | 1 | 1 |
| Prostacyclin receptor | Homo sapiens (human) | IC50 | 0.2600 | 1 | 1 |
| Prostacyclin receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | IC50 | 0.0156 | 2 | 2 |
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | Ki | 0.0121 | 3 | 3 |
| Prostaglandin E2 receptor EP1 subtype | Mus musculus (house mouse) | Ki | 0.0060 | 2 | 2 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | IC50 | 0.0087 | 6 | 6 |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | IC50 | 0.0052 | 1 | 1 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | Ki | 0.0092 | 6 | 6 |
| Prostaglandin E2 receptor EP2 subtype | Mus musculus (house mouse) | Ki | 0.0220 | 2 | 2 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | IC50 | 0.0020 | 2 | 2 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | Ki | 0.0020 | 4 | 4 |
| Prostaglandin E2 receptor EP3 subtype | Mus musculus (house mouse) | Ki | 0.0050 | 2 | 2 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | IC50 | 0.0031 | 7 | 7 |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | IC50 | 0.0021 | 1 | 1 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | Ki | 0.0010 | 8 | 8 |
| Prostaglandin E2 receptor EP4 subtype | Mus musculus (house mouse) | Ki | 0.0031 | 2 | 2 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | Ki | 0.0610 | 1 | 2 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | Ki | 0.0610 | 1 | 2 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | Ki | 0.0610 | 1 | 2 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.0400 | 1 | 1 |
| Solute carrier family 22 member 20 | Mus musculus (house mouse) | Ki | 18.0985 | 1 | 2 |
| Solute carrier family 22 member 6 | Mus musculus (house mouse) | Ki | 3.3942 | 1 | 2 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 3.0640 | 1 | 1 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 3.1600 | 1 | 1 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 6.4990 | 1 | 1 |
| Vasopressin V1a receptor | Homo sapiens (human) | IC50 | 10.0000 | 1 | 3 |
| Vasopressin V1a receptor | Homo sapiens (human) | Ki | 0.0737 | 4 | 4 |
| Vasopressin V1a receptor | Rattus norvegicus (Norway rat) | Ki | 0.0610 | 1 | 1 |
| Vasopressin V1b receptor | Homo sapiens (human) | Ki | 3.8910 | 2 | 2 |
| Vasopressin V1b receptor | Rattus norvegicus (Norway rat) | Ki | 0.0610 | 1 | 1 |
| Vasopressin V2 receptor | Homo sapiens (human) | Ki | 3.6813 | 3 | 3 |
| Vasopressin V2 receptor | Rattus norvegicus (Norway rat) | Ki | 0.0700 | 2 | 3 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | EC50 | 0.0019 | 1 | 1 |
| Oxytocin receptor | Homo sapiens (human) | EC50 | 0.0052 | 18 | 27 |
| Oxytocin receptor | Mus musculus (house mouse) | EC50 | 0.0320 | 1 | 2 |
| Oxytocin receptor | Homo sapiens (human) | Kd | 0.0067 | 1 | 1 |
| Prostacyclin receptor | Homo sapiens (human) | EC50 | 0.3470 | 1 | 1 |
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | EC50 | 0.0037 | 1 | 1 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | EC50 | 0.1381 | 5 | 5 |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | EC50 | 0.0096 | 2 | 2 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | EC50 | 0.0025 | 1 | 1 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | EC50 | 0.0028 | 5 | 5 |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | EC50 | 0.0021 | 2 | 2 |
| Prostaglandin F2-alpha receptor | Homo sapiens (human) | EC50 | 0.2500 | 1 | 1 |
| Vasopressin V1a receptor | Homo sapiens (human) | EC50 | 0.0316 | 9 | 15 |
| Vasopressin V1b receptor | Homo sapiens (human) | EC50 | 3.4137 | 7 | 11 |
| Vasopressin V2 receptor | Homo sapiens (human) | EC50 | 1.1287 | 4 | 8 |